The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
Consultants have held several strikes over the past year, which has hobbled the NHS as it tries to grapple with financial constraints and backlogs caused by the coronavirus pandemic.
A survey by the Saskatchewan College of Pharmacy Professionals comes just weeks after its Ontario counterpart revealed the findings of a similar probe and announced a zero-tolerance stance on corporate pressures in pharmacy.
